Targeted versus global approaches to the management of hypercholesterolaemia
- 1 September 2008
- journal article
- other
- Published by SAGE Publications in Perspectives in Public Health
- Vol. 128 (5) , 248-254
Abstract
Aims: The role of statins in secondary prevention of cardiovascular disease is well established. However, there is debate about the most effective approach to primary prevention. This study simulated the effects of directed versus global approaches for intervention on coronary heart disease (CHD) event rates. Methods: A primary prevention population was generated by computer simulation derived from data from the National Health Survey for England. The efficacy of reductions in cholesterol, treatment to cardiovascular risk targets and effects of phytosterols or statins were assessed. Results: A 0.5 mmol/L reduction in population total cholesterol would result in a 10.4% reduction in CHD events, while 1.0 mmol/L, 1.5 mmol/L and 2.0 mmol/L reductions would achieve 21.0%, 30.6% and 41.9% reductions respectively. In statin-based cardiovascular risk targeted strategies, use of simvastatin 40 mg would result in 1.8% reduction by UK National Service Framework targets of 30%/decade CHD risk and 7.2% reduction in events for a 20%/decade target assuming perfect adherence. Similarly, aggressive primary prevention with 40 mg atorvastatin would result in a 2.5% or 10% reduction in events. Universal use of 10 mg simvastatin following an over-the-counter approach would result in a 25% reduction in CHD events. In contrast, whole population consumption of sitostanol/sitosterol products would result in 11.8% reduction. Conclusion: Targeting and treating high-risk individuals may be beneficial for them and rewarding for medical practitioners. However, this approach has minimal effects on the population burden of atherosclerotic disease. This study suggests that universal therapy with phytosterols and/or wider availability of statins has the potential to dramatically decrease rates of CHD.Keywords
This publication has 36 references indexed in Scilit:
- Healthy Lifestyle Factors in the Primary Prevention of Coronary Heart Disease Among MenCirculation, 2006
- Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysisHeart, 2005
- Simvastatin over the counterDrug and Therapeutics Bulletin, 2005
- Consumer behavior in the setting of over-the-counter statin availability: Lessons from the Consumer Use Study of OTC MevacorThe American Journal of Cardiology, 2004
- The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: Is this a good idea?The American Journal of Cardiology, 2004
- The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery diseaseThe American Journal of Cardiology, 2004
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991